Albemarle Strategic Growth Presentation

Adjusted EBITDA - Continuing Operations (twelve months ended) ($ in thousands) Net income attributable to Albemarle Corporation Depreciation and amortization Non-recurring and other unusual items (excluding items associated with interest expense) Interest and financing expenses Income tax expense Non-operating pension and OPEB items Adjusted EBITDA Net sales Adjusted EBITDA margin Twelve Months Ended Sep 30, 2022 Dec 31, 2022 Mar 31, 2023 Jun 30, 2023 Sep 30, 2023 $ 1,553,547 283,515 $ 2,689,816 $ 3,675,013 $ 3,918,283 $ 3,323,601 300,841 321,538 343,630 371,362 215,768 28,671 (14,691) 198,217 228,689 104,240 122,973 121,916 106,084 105,725 381,510 390,588 587,021 540,990 335,501 (77,752) (57,032) (51,151) (45,501) (39,854) $ 2,460,828 $ 3,475,857 $ 4,639,646 $ 5,061,703 $ 4,325,024 5,593,330 $ 7,320,104 $ 8,772,628 9,663,225 $ 9,882,016 44 % 47 % 53 % 52 % 44 % See above for a reconciliation of adjusted EBITDA and pro-forma adjusted EBITDA, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP. See above for a reconciliation of pro-forma net sales, the non-GAAP financial measure, to net sales, the most directly comparable financial measure calculated and reported in accordance with GAAP. Albemarle 38

View entire presentation